The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) is showcasing new clinical data this week from trials assessing the efficacy of IL-23 blockers, Tremfya (guselkumab) and JNJ-2113, in the treatment of psoriasis. The findings, derived from a late-stage study, reveal that Tremfya facilitated clear skin within 28 weeks for a subgroup of patients with a short disease duration, underscoring the importance of early intervention as part of a personalized therapeutic strategy.
Efficacy of JNJ-2113 in Moderate-to-Severe Psoriasis
In a separate Phase II trial focusing on moderate-to-severe plaque psoriasis, JNJ-2113 demonstrated significant biochemical and physiological responses compared to a placebo. This oral peptide shows promise across a range of potential indications and is being developed in collaboration with Protagonist Therapeutics (NASDAQ: PTGX), following a partnership established in 2017.
Conclusion: Advancing Treatment Strategies in Psoriasis Care
The clinical results presented by Janssen highlight the potential of both Tremfya and JNJ-2113 in transforming psoriasis treatment. With a focus on early intervention and innovative therapies, Johnson & Johnson is poised to enhance patient outcomes in this challenging condition.-Fineline Info & Tech
